Price-to-Projected Revenue Ratio: Alcon (ALC)

Corporate emblem and logo of Alcon Inc. (ALC)

Alcon Inc. strives for global leadership in ophthalmology by integrating surgical technologies with the vision correction market. The company's capital is generated through the sale of innovative lenses, surgical equipment, and eye care products. The dynamics of the forward P/S ratio, where 1.10 represents the latest level, reflect market sentiment amid a complete absence of geopolitical risks to the business.

ALC Alcon Inc: Market Cap to Projected Revenue in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Alcon Inc.

- current price and projected stock value:
Stock Price Alcon|ALC - Consensus Target
- company stock exchange capitalization indicators:
Market Value Alcon Corp|ALC - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Alcon|ALC - Accounting Capitalization|Market Cap to Net Assets Ratio alcon.com|ALC - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Alcon Inc.|ALC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Alcon Inc.|ALC - Company Aggregate Debt|Debts to Book Capitalization Alcon Corp|ALC - Company Long-Term Liabilities|Company Current Liabilities Alcon|Quick Ratio alcon.com
- business earnings and investment ratios data:
ALC - Net Profit|Expected Profit Alcon Inc.|ALC - Price to Earnings Ratio|Forward P/E Multiple Alcon Vision|ALC - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alcon Corp|ALC - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Alcon|ALC - Earnings per share for the trailing year|Quarterly EPS earnings growth alcon.com|ALC - Earnings growth in current year|Net earnings per share growth forecast for next year Alcon Inc.
- sales and revenue indicators:
ALC - Company Sales Revenue|Company Projected Revenue Alcon|ALC - Market Cap to Revenue|Forward P/S Multiple Alcon Corp
Fundamental company valuation:Alcon ALC
Product sample of Alcon Inc.

The forward P/S reflects the ratio of the current market value of Alcon Inc. (ALC) to expected annual sales volume, measuring the premium for future growth. This metric serves as a stress-testing tool, identifying asset overbought conditions when a gap emerges between price and actual revenue forecasts. By analyzing the forward P/S value, an investor can justify the valuation through the dominance of Alcon Inc. (ALC) equipment in ophthalmological operating rooms and a steady patient inflow.

Competitors of Alcon Inc. (ALC)

Forward P/S Multiple BLCO (Bausch + Lomb)|GKOS - Forward Price-to-Revenue Multiple|APLS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Belite Bio, Inc|Ocular Therapeutix (OCUL) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HROW|Forward Price-to-Revenue Multiple VRDN|LENZ: Forward Price to Sales|Forward P/S Multiple OCS|Market Cap to Expected Sales Ratio EyePoint Corp|Price-to-Projected Revenue Ratio Kodiak Sciences Inc. KOD|ALDX: Market Cap to Projected Revenue|Kala Pharmaceuticals - Forward P/S Multiple|Opus Genetics Inc (IRD) - Forward Price-to-Revenue Multiple|OKYO (okyopharma.com) - Forward Price-to-Revenue Multiple|ADVM - Market Cap to Expected Sales Ratio|OTLK (Outlook Therapeutics) - Forward P/S Multiple|Forward P/S Multiple clearsidebio.com|Price-to-Projected Revenue Ratio NovaBay Pharmaceuticals (NBY)|Price-to-Projected Revenue Ratio KPRX (kiorapharma.com)|Forward P/S Multiple ALIM (Alimera Sciences, Inc.)|EYEN - Forward Price-to-Revenue Multiple|GHSI - Price-to-Projected Revenue Ratio|Future Price to Revenue OCUP|OPT: Forward P/S Multiple